Back to results
US 8,541,433 B2Granted
Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
AssigneeActelion Pharmaceuticals Ltd.
InventorsMartine Clozel, Urs Regenass
Life of this patent
Estimating the term…
Abstract
The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.
Claims4
A. method for the treatment of multi-drug resistant ovarian cancer, comprising administering, simultaneously, separately or over a period of time, to a patient in need thereof, a compound of formula (I):
- in free or pharmaceutically acceptable salt form, in combination with paclitaxel, in free or pharmaceutically acceptable salt form.
Dependencies are inferred from the claim text.